Panel Discussion: Setting the Boundaries of What’s Clinically Achievable in RAS Therapy Defining the Realistic Therapeutic Window for Next-Generation Strategies

• How does differential targeting influence tolerability and depth of pathway inhibition, and where do selective versus broader approaches ultimately succeed or fail?
• How should mutant-selective versus wild-type-sparing strategies be balanced to deepen inhibition without breaching tolerability limits, especially when layering multi-agent regimens?
• How can safety-first design principles, PK/PD-guided exposure management, mechanism-based toxicity mitigation, and early integration of safety margins, enable continuous pathway suppression and long-term disease control?

Speakers:

Thomas Spires

Senior Director Translational Medicine For Adagrasib Development Lead

Bristol Myers Squibb

Federico Innocenti

Senior Director, Clinical Development - Solid Tumors

BeOne Medicines

Luke Pase

Chief Technology Officer

Anocca AB